COPD is associated with multiple comorbidities such as cardiovascular diseases, depression, and diabetes mellitus. Bronchodilators are often used in the management of COPD, but can also have an effect on comorbidities. We caught up with editorial board member Professor Mario Cazzola (University of Rome ‘Tor Vergata’, Rome, Italy) to discuss bronchodilator selection in patients with COPD and the importance of minimising the risk of drug interactions.
‘What’s New in COPD Pharmacology’ was presented at CHEST Congress 2022, 27-29 June 2022.
Questions
- What are the potential interactions between bronchodilators and drugs used to treat comorbidities? (0:42)
- What questions should be asked when selecting bronchodilators for COPD? (5:19)
Disclosures: Mario Cazzola has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
